{'fraction_non_alphanumeric': 0.028156996587030716, 'fraction_numerical': 0.0017064846416382253, 'mean_word_length': 6.33125, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
A Review of Studies Assessing Cannabidiol’s (CBD) Therapeutic Action and Potentials in Respiratory Diseases

Cannabidiol (CBD) is the major non-mind-altering section of the hairy glands of hemp plant that can be named‘cannabinoids’ (CBs). Cannabinoid in the pharmacology field is becoming an extensive subject specificallytowards the therapeutic characteristics of cannabinoid receptor agonists. Examples such as analgesia,muscle relaxation, immunosuppressive, antiinflammatory and anti-allergic effects, mood improvement,appetite stimulation, antiemesis, lowering of intraocular pressure, bronchodilatation, neuroprotection, andanti-neoplastic effects. Although this vast knowledge about the therapeutic properties of CBs, their clinicaluses remains a controversy and very limited. However, the focus now has been on CBD that constitutes upto 40% of the extract of the Cannabis and represents one of the most attractive prospects for therapeutic useowing to its extraordinary lack of both perceptual and psychoactive behavior. Finally, CBD is regarded as animportant putative lead compound to produce cannabinomimetic drugs because of its excellent tolerabilityin humans.